Skip to main content
Premium Trial:

Request an Annual Quote

Precipio Diagnostics Raises $1.8M

NEW YORK (GenomeWeb News) – Precipio Diagnostics has raised $1.8 million in a Series B financing round, Connecticut Innovations, the lead investor in the round, said today.

Along with CI, which invested $750,000 in the round through its Eli Whitney Fund, Ironwood Capital, Enhanced Capital, Kuzari Capital, and individual investors participated in the financing.

Based in New Haven, Conn., Precipio provides pathology services, with a focus on cancer diagnostics. It began operations about a year-and-a-half ago and has exclusive deals with Yale School of Medicine and Yale-New Haven Hospital to analyze patients samples and report on their findings. It also licenses technologies from Yale that include a tumor profiling test suite and a prognostic biomarker for ovarian cancer.

Among the tests offered by Precipio are those based on PCR, cytogenetics, fluorescent in situ hybridization, and other technologies.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.